Relative contribution of hepatitis B and C viruses in primary liver cancer in China: A systematic review and meta-analysis

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES Journal of Infection Pub Date : 2024-10-03 DOI:10.1016/j.jinf.2024.106298

Baojiang Wen , Liger Te , Changsen Bai , Wenna Jiang, Duo Zuo, Qianhui Hao, Jiayi Wang, Li Ren

{"title":"Relative contribution of hepatitis B and C viruses in primary liver cancer in China: A systematic review and meta-analysis","authors":"Baojiang Wen , Liger Te , Changsen Bai , Wenna Jiang, Duo Zuo, Qianhui Hao, Jiayi Wang, Li Ren","doi":"10.1016/j.jinf.2024.106298","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>China, which has the largest number of patients with primary liver cancer (PLCs), lacks data on the overall prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in PLCs. We aimed to comprehensively assess the seroprevalence of HBV and HCV among PLCs in China.</div></div><div><h3>Methods</h3><div>We included and pooled observational studies reporting seroprevalence of HBsAg and anti-HCV antibodies among PLCs in China by searching PubMed, Web of Science, Cochrane, Scopus, Embase, CNKI, Wanfang, and CBM. Multivariate meta-regression and subgroup analyses were used to explore sources of heterogeneity, and publication bias was assessed by funnel plots and Egger's test. PROSPERO registration number is CRD42023450382.</div></div><div><h3>Results</h3><div>A total of 217 eligible studies were included in the meta-analysis. The estimated seroprevalence of HBV and HCV in PLCs was 75.09% (95% CI 73.12–77.02) and 11.82% (95% CI 9.79–14.00), respectively. After stratifying and analysing subgroups by region and study period, we found geographic differences in HBV and HCV prevalence among PLCs, with an overall increasing trend in the proportion of HBV and a decreasing trend in the proportion of HCV as well as co-infections in the last 40 years.</div></div><div><h3>Conclusions</h3><div>HBV and HCV infections still account for a high proportion of PLCs in China.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 6","pages":"Article 106298"},"PeriodicalIF":14.3000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163445324002329","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

China, which has the largest number of patients with primary liver cancer (PLCs), lacks data on the overall prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in PLCs. We aimed to comprehensively assess the seroprevalence of HBV and HCV among PLCs in China.

Methods

We included and pooled observational studies reporting seroprevalence of HBsAg and anti-HCV antibodies among PLCs in China by searching PubMed, Web of Science, Cochrane, Scopus, Embase, CNKI, Wanfang, and CBM. Multivariate meta-regression and subgroup analyses were used to explore sources of heterogeneity, and publication bias was assessed by funnel plots and Egger's test. PROSPERO registration number is CRD42023450382.

Results

A total of 217 eligible studies were included in the meta-analysis. The estimated seroprevalence of HBV and HCV in PLCs was 75.09% (95% CI 73.12–77.02) and 11.82% (95% CI 9.79–14.00), respectively. After stratifying and analysing subgroups by region and study period, we found geographic differences in HBV and HCV prevalence among PLCs, with an overall increasing trend in the proportion of HBV and a decreasing trend in the proportion of HCV as well as co-infections in the last 40 years.

Conclusions

HBV and HCV infections still account for a high proportion of PLCs in China.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乙型肝炎病毒和丙型肝炎病毒在中国原发性肝癌中的相对作用：系统回顾和荟萃分析。

目的：中国是原发性肝癌（PLC）患者人数最多的国家：中国是原发性肝癌（PLC）患者人数最多的国家，但缺乏有关PLC中乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）总体流行率的数据。我们旨在全面评估中国原发性肝癌患者中 HBV 和 HCV 的血清流行率：通过检索 PubMed、Web of Science、Cochrane、Scopus、Embase、CNKI、万方和 CBM，我们纳入并汇总了报道中国 PLC 中 HBsAg 和抗 HCV 抗体血清流行率的观察性研究。采用多变量元回归和亚组分析探讨异质性的来源，并通过漏斗图和Egger检验评估发表偏倚。PROSPERO注册号为CRD42023450382：共有 217 项符合条件的研究被纳入荟萃分析。估计的 HBV 和 HCV 血清流行率分别为 75.09% (95% CI 73.12-77.02) 和 11.82% (95% CI 9.79-14.00)。按地区和研究时期进行分层和分组分析后，我们发现 PLC 中的 HBV 和 HCV 感染率存在地域差异，在过去 40 年中，HBV 感染率总体呈上升趋势，HCV 感染率和合并感染率呈下降趋势：结论：HBV 和 HCV 感染在中国 PLC 中仍占很高比例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Infection 医学-传染病学

CiteScore

45.90

自引率

3.20%

发文量

475

审稿时长

16 days

期刊介绍： The Journal of Infection publishes original papers on all aspects of infection - clinical, microbiological and epidemiological. The Journal seeks to bring together knowledge from all specialties involved in infection research and clinical practice, and present the best work in the ever-changing field of infection. Each issue brings you Editorials that describe current or controversial topics of interest, high quality Reviews to keep you in touch with the latest developments in specific fields of interest, an Epidemiology section reporting studies in the hospital and the general community, and a lively correspondence section.